Atrial fibrillation in cancer: balancing competing risks

Atrial fibrillation management in patients with cancer requires a shifting balance between prevention of ischaemic stroke, protection from procedure-related and treatment-related harm, and preservation of each patient’s goals and quality of life. Tumour-related thrombosis can add risk beyond AF itself, while thrombocytopenia, anaemia, organ dysfunction and recent surgery can magnify bleeding. The result is not a single protocol but a plan reviewed as the cancer journey and anticoagulant exposure change.

AF may be a consequence of surgery, radiation, cardiotoxic therapy, infection, anaemia or fluid shifts, yet it may also be longstanding AF discovered during oncology treatment. Its burden can fluctuate, and the appropriate response depends on whether AF is causing symptoms, whether cancer treatment is curative or palliative, and whether important causes are reversible.

Why cancer changes the risk calculation

Cancer and AF influence one another. Tumours can create a systemic prothrombotic state, while surgery, chemotherapy, radiotherapy and supportive medicines may trigger AF. Conversely, AF can complicate cancer treatment by causing tachycardia, hypotension, breathlessness or reduced exercise tolerance, making it harder to distinguish arrhythmia from anaemia, infection, pulmonary embolism or cardiac dysfunction.

The decision starts with the treatment plan rather than the rhythm label alone. Clinicians should establish the likely duration of AF, prior stroke or venous thromboembolism, current cancer stage and treatment intent, recent procedures and the patient’s priorities. For a broader evidence base, the journal’s current articles and reviews provide useful context for electrophysiology, pacing and clinical management.

A practical classification separates stable AF with established therapy from new or worsening AF during active treatment. Patients receiving intensive chemotherapy or surgery may need short-term plans focused on safety and reversibility, whereas those in survivorship or receiving long-term cancer therapy require durable stroke prevention. Regular reassessment is essential because the balance can change over weeks or months.

Measuring thromboembolic and bleeding risk

CHA₂DS₂-VASc remains a useful starting point for estimating AF-related stroke risk, but it does not capture every cancer-specific variable. Metastatic disease, active malignancy, treatment phase and tumour-associated hypercoagulability may increase risk beyond the score alone. Conversely, severe thrombocytopenia or an active bleeding source may materially change the safety of anticoagulation.

Bleeding risk should be assessed directly rather than inferred from the absence of an anticoagulant contraindication. Relevant factors include platelet count and function, haemoglobin, renal and hepatic function, gastrointestinal or genitourinary lesions, intracranial disease, recent biopsy or surgery, and the use of antiplatelets, NSAIDs or other medicines that increase bleeding. HAS-BLED can identify modifiable risks, but it should not be used on its own as a reason to withhold indicated anticoagulation.

When patent foramen ovale is also present, an educational patient-centred PFO case illustrates the need for individualised assessment. PFO closure is not a routine response to AF or cancer, and suspected paradoxical embolism requires careful investigation across neurological, oncological and cardiac domains. The patient should understand that closure decisions are separate from AF anticoagulation.

Selecting anticoagulation around active treatment

A direct oral anticoagulant, or DOAC, is often preferred for eligible patients with non-valvular AF, including many people with stable cancer, because it reduces the need for routine international normalised ratio monitoring. Warfarin remains important where a DOAC is unsuitable, particularly with mechanical heart valves, moderate-to-severe rheumatic mitral stenosis, severe renal impairment or substantial interactions with cancer treatment.

The choice should account for the bleeding profile of the tumour and treatment. Patients with thrombocytopenia, mucosal lesions or recent surgery may need dose modification, temporary interruption, alternative monitoring or joint planning with haematology. Local platelet thresholds and peri-procedural protocols vary, so decisions should not rely on a universal dose or count without assessing the whole clinical picture.

Anticoagulation for AF stroke prevention should not be confused with therapeutic anticoagulation for cancer-associated thrombosis. Their indications, doses and durations can differ. Decisions around biopsy, surgery, gastrointestinal bleeding, thrombocytopenia and transfusion support should be made jointly by oncology, cardiology, haematology and the procedural team, with clear instructions about when to restart treatment.

Preventing interactions and medication harm

Medication review must include chemotherapy, targeted agents, antiemetics, antibiotics, analgesics, antiplatelets, over-the-counter products and complementary medicines. DOACs are affected by strong P-glycoprotein and CYP3A4 inhibitors or inducers, including some azoles, macrolide antibiotics and antiretroviral medicines. Warfarin has a different interaction profile and may be affected by antibiotics, anti-emetics and several antineoplastic agents.

Supportive treatment can also amplify risk. Ibuprofen and other NSAIDs increase gastrointestinal bleeding and may affect kidney function, particularly during chemotherapy. High-dose or prolonged paracetamol can raise INR in patients taking warfarin. Anti-emetics with QT-prolonging effects may complicate rhythm-control therapy, while amiodarone, digoxin, beta-blockers and rate-control medicines require attention to hypotension, renal clearance and heart function.

In Australia, Medicare subsidises many consultations, and many standard AF medicines are listed on the Pharmaceutical Benefits Scheme, but subsidy does not remove the need for interaction monitoring or an individualised plan. Community pharmacists can provide medication reviews and services such as MedsCheck. A written plan should identify who is actioning the next review, which laboratory results are required and how changes will be communicated after a hospital admission.

Coordinating care across Australian services

A shared care plan should state the anticoagulant, its indication, monitoring requirements, bleeding precautions and the thresholds for review. It should also record who owns decisions about cancer treatment, rate or rhythm control, anticoagulation and emergency care. This avoids contradictory advice, particularly when patients receive treatment in different public and private settings or move between metropolitan and regional hospitals.

Specialist cancer services operate across Melbourne, Sydney, Brisbane, Adelaide and Perth, while regional hospitals often manage part of treatment locally. Teleoncology and multidisciplinary teleconferences can connect regional teams with cardiology and haematology expertise. These networks are especially valuable when oncology appointments, pathology results and anticoagulant reviews occur in different locations, although travel, transport and time away from home remain significant barriers for some patients.

Equity requires attention in northern Australia and other remote communities. Aboriginal Community Controlled Health Services, Aboriginal medical practitioners and community health workers can be central to culturally safe care for Aboriginal and Torres Strait Islander patients in places such as Darwin, Alice Springs and Cairns. Reviewing access to transport, affordable medicines, pathology and follow-up is as important as arranging the prescription itself.

Reassessing as cancer care evolves

The risk profile changes with imaging results, new episodes of thrombocytopenia, changes in kidney or liver function, surgery, infection and transitions between oral and intravenous treatment. AF therapy should therefore be reviewed after major treatment milestones, not only when the rhythm changes. A patient who remains at high embolic risk may still need anticoagulation even if AF appears infrequent or cardioversion has restored sinus rhythm.

For elective cardioversion, standard anticoagulation before and after the procedure or a transoesophageal echocardiography-guided strategy applies; cancer does not remove AF-related thromboembolic risk. Around ablation, anticoagulation decisions depend on stroke risk, procedure-related bleeding and recovery. Medication simplification may become appropriate when treatment burden exceeds benefit, particularly in advanced disease, but deprescribing should follow a documented discussion rather than an informal decision at a single appointment.

The Journal of Arrhythmia, the official publication of the Asia Pacific Heart Rhythm Society and Japanese Heart Rhythm Society, provides peer-reviewed material on these issues. Readers can explore themed special issues for focused collections and use them when developing local education for oncology, cardiology, pharmacy and nursing teams. Important research gaps include newer cancer therapies, thrombocytopenia, remote monitoring, culturally safe care and patient-reported outcomes.

Use this framework in every AF assessment: confirm the indication and current anticoagulant, complete an interaction review at each treatment change, and name the clinician responsible for reassessing stroke risk, bleeding and goals of care. Read the journal’s latest evidence, translate it into local protocols, share useful cases with colleagues and trainees, and contribute research that reflects the full complexity of cancer care.